ERBB2 and breast carcinoma: For example, ESR1::CCDC170 has been detected in 6%–8% of Luminal B breast cancers40,41, a more aggressive and endocrine-resistant subtype of HR+/HER2‒ breast cancer, and has been shown to promote increased tumor invasiveness and endocrine resistance.